Results 161 to 170 of about 2,652 (202)
Antiviral activity of brincidofovir on parvovirus B19 [PDF]
Antiviral Research, 2019 Parvovirus B19 (B19V), a single-stranded DNA virus in the family Parvoviridae, is a human pathogenic virus responsible for a wide range of clinical manifestations. Currently there is no approved antiviral therapy for parvovirus infection. The acyclic nucleoside phosphonate cidofovir (CDV) has been demonstrated to inhibit replication of B19V in vitro ...
GLORIA BUA +2 more
exaly +5 more sources
Brincidofovir for Polyomavirus-Associated Nephropathy After Allogeneic Hematopoietic Stem Cell Transplantation [PDF]
American Journal of Kidney Diseases, 2015 Polyomavirus-associated nephropathy (PVAN) is common in patients who have undergone kidney transplantation and has been reported in hematopoietic stem cell (HSC) transplant recipients. Aside from reduction of immunosuppression, few therapeutic options exist for treatment of PVAN.
Yeon Jou Lee, Surya V Seshan
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The use of brincidofovir for the treatment of mixed dsDNA viral infection
Journal of Clinical Virology, 2016Double-stranded DNA (dsDNA) viral infections constitute a major complication following solid organ and stem cell transplantation. Few therapeutic options are currently available for the treatment of such infections in highly immunocompromised hosts. Brincidofovir is an oral investigational drug with broad antiviral activity against dsDNA viruses in ...
Jose F Camargo +2 more
exaly +3 more sources
Brincidofovir as Salvage Therapy for Adenovirus Disease in Intestinal Transplant Recipients
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2018BackgroundAdenoviruses are double‐stranded DNA viruses that typically cause mild self‐limiting respiratory, ocular, and gastrointestinal infections. In immunocompromised patients, especially transplant recipients, the infection can be severe, with dissemination and multiorgan failure. In intestinal transplant recipients, the incidence is as high as 57%.
Nimisha Sulejmani +6 more
openaire +2 more sources
Treatment efficacy of cidofovir and brincidofovir against clade II Monkeypox virus isolates
Antiviral ResearchWhile historically confined to endemic areas, Monkeypox virus (MPXV) infection has increasingly garnered international attention due to sporadic outbreaks in non-endemic countries in the last two decades and its potential for human-to-human transmission.
Jérémie Prévost +2 more
exaly +3 more sources
Initial Experience Treating HPV-Related Laryngeal Diseases with Oral Brincidofovir: A Pilot Study
Annals of Otology, Rhinology & Laryngology, 2021Objective: To determine if brincidofovir, an oral analog of cidofovir that achieves high tissue levels of the active metabolite with low systemic toxicity, has an observable effect on HPV-related disease of the larynx. Methods: Two patients with laryngeal recurrent respiratory papillomatosis (one each of genotypes 6 and 11) and 1 with recurring ...
openaire +2 more sources
Abstract 3043: Preclinical efficacy assessment of brincidofovir against glioblastoma
Cancer ResearchAbstract Introduction: Clinical use of the cytidine-analogue antiviral, cidofovir (CDV), is limited by nephrotoxicity. The lipid-conjugated CDV, brincidofovir (BCV), is characterized by a lack of nephrotoxicity, as well as superior activity compared to CDV. The objectives of this study were to examine
Kyounghee Seo +4 more
openaire +1 more source